Medicus Pharma Ltd. Commo... (MDCX)

Medicus Pharma (NASDAQ:MDCX) announced that Stonegate Capital Partners has initiated coverage on the company.  Stonegate analysts wrote that with the closing of its $8 million debenture financing, Med...

Dallas, Texas--(Newsfile Corp. - September 24, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX): Stonegate Capital Partners initiates their coverage on Medicus Pharma Ltd.

The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix, ...

Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's recent progress across its drug development pipeline. Bokhari shared that Medicus Pharma has closed its acquisit...

Medicus Pharma (NASDAQ:MDCX) announced Thursday that it has entered into a financing agreement with Yorkville Advisors Global, through its fund YA II PL, Ltd., raising $8 million in non-dilutive deben...

The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV r...

Medicus Pharma (NASDAQ:MDCX) announced that its SKNJCT-004 Phase 2 clinical study, a non-invasive treatment for Basal Cell Carcinoma (BCC) of the skin, has begun patient recruitment in Cleveland clini...

Medicus Pharma (NASDAQ:MDCX) reported that it has completed its previously announced acquisition of Antev Limited, a UK-based clinical-stage drug development company.  Medicus said it has acquired 98....

Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 b...

Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's progress in its Phase 2 study targeting basal cell carcinoma — the most common form of skin cancer. Bokhari shar...